# A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

> **NCT05741242** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Jaime Leandro Foundation for Therapeutic Cancer Vaccines** · enrollment: 136 (estimated)

## Conditions studied

- Cancer
- Solid Tumor

## Interventions

- **BIOLOGICAL:** Personalized Synthetic Long Peptide Vaccine

## Key facts

- **NCT ID:** NCT05741242
- **Lead sponsor:** Jaime Leandro Foundation for Therapeutic Cancer Vaccines
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-11-30
- **Primary completion:** 2027-01
- **Final completion:** 2029-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05741242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05741242, "A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05741242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*